Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536 [0.03%]
有关WO2018102536使用艾替利单抗和纳武单抗的肿瘤免疫联合疗法的专利评估
Martin Perez-Santos,Maricruz Anaya-Ruiz,Irma Herrera-Camacho et al.
Martin Perez-Santos et al.
Introduction: TIGIT is an inhibitory receptor expressed by lymphocytes that suppresses the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of TIGIT and conseq...
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019) [0.03%]
2014-2019年HDAC6抑制剂在神经退行性疾病中的专利分析
Sida Shen,Alan P Kozikowski
Sida Shen
Introduction: Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members. An increasing amount of evidence from clinical and preclinical research demonstrates the potential of HDAC6 inhibition as an ...
Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present) [0.03%]
与痕量胺相关受体1(TAAR1)相互作用的调节剂：专利综述(2010-今)
Michele Tonelli,E Cichero
Michele Tonelli
Introduction: The greater interest in TAAR1-mediated potential for the treatment of different pathologies, especially those related to CNS disorders, has given a considerable boost to the search for developing TAAR1-selective small molecule...
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018 [0.03%]
基于小分子和肽的CXCR4调节剂作为治疗剂。2010年至2018年的专利回顾
Yesim A Tahirovic,Sameshnee Pelly,Edgars Jecs et al.
Yesim A Tahirovic et al.
Introduction: The chemokine receptor CXCR4 has been under intense study due to the central role it plays in immune system regulation and the pathology of many human diseases. The FDA approval of the first CXCR4 antagonist drug Plerixafor (i...
Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors [0.03%]
药物再定位在抗癌疗法中的应用——来自质子泵抑制剂的启示
Enrico Pierluigi Spugnini,Stefano Fais
Enrico Pierluigi Spugnini
Introduction: Worldwide, the annual expenditure on anticancer drugs is grossly calculated to be in the order of US$100 billion, and is expected to escalate up to $150 billion by 2020. It is evident that the vast majority of the most recentl...
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present) [0.03%]
血友病甲型因子XI(a)抑制剂抗凝专利盘点(2016-至今)
Rami A Al-Horani
Rami A Al-Horani
Introduction: Anticoagulation without bleeding is an ideal goal in treating thrombosis, however, this goal has not been achieved. All current anticoagulants are associated with significant bleeding which limits their safe use. Genetic and p...
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present) [0.03%]
过氧化物酶体增殖激活受体激动剂和拮抗剂专利回顾(2014-今)
Ichiro Takada,Makoto Makishima
Ichiro Takada
Introduction: Peroxisome proliferator-activated receptors (PPARs), PPARα, PPARδ, and PPARγ, play an important role in the regulation of various physiological processes, specifically lipid and energy metabolism and immunity. PPARα agonis...
Tian Lu,Wenchao Lu,Cheng Luo
Tian Lu
Introduction: The bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra-terminal (BET) family, functions as an 'epigenetic reader' that binds to acetylated lysine (KAc) residues on histone tails sophisticatedly regu...
Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review [0.03%]
医药化学中GPR40/FFAR1调节剂的最新进展（2016-2019）：专利综述
Zheng Li,Zongtao Zhou,Luyong Zhang
Zheng Li
Introduction: The activation of free fatty acid receptor 1 (FFAR1) induces insulin secretion in a glucose-dependent manner, and thereby is considered as an attractive anti-diabetic target. The clinical studies provided a lot of evidence tha...
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications [0.03%]
新型P2X3和P2X2/3受体拮抗剂及其潜在治疗应用的进展更新
Gabriella Marucci,Diego Dal Ben,Michela Buccioni et al.
Gabriella Marucci et al.
Introduction: Purinergic P2X3-P2X2/3 receptors are placed in nociceptive neurons' strategic location and show unique desensitization properties; hence, they represent an attractive target for many pain-related diseases. Therefore, a broad i...